lansoprazole has been researched along with zithromax in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (43.48) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 6 (26.09) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cammarota, G; Cuoco, L; Fedeli, G; Gasbarrini, G; Montalto, M; Papa, A; Tursi, A; Veneto, G | 1 |
| Alvisi, V; Caselli, M; Gasbarrini, G; Gaudenzi, P; Luzzi, I; Ruina, M; Sartori, S; Trevisani, L; Tursi, A | 1 |
| Abbasciano, V; Caselli, M; Ruina, M; Sartori, S; Trevisani, L; Verdianelli, G | 1 |
| Campa, M; Favini, P; Malizia, T; Marchetti, F; Pizzarelli, G; Senesi, S; Tejada, M | 1 |
| Abbasciano, V; Caselli, M; Galvani, F; Ruina, M; Sartori, S; Trevisani, L; Verdianelli, G | 1 |
| Blandino, G; Carbone, M; Ciliberti, FA; Cusumano, V; De Sarro, A; De Sarro, GB; Fera, MT; Riggio, G | 1 |
| Addolorato, G; Armuzzi, A; Cammarota, G; Cannizzaro, O; Cianci, R; Gasbarrini, A; Gasbarrini, GB; Papa, A | 1 |
| Della Monica, P; Lombardo, L; Masoero, G; Pera, A | 1 |
| Bohr, U; Glasbrenner, B; Möricke, A; Riediger, C; Trautmann, M; Vogt, K | 1 |
| Bildfell, R; Dewey, CE; Friendship, RM; Melnichouk, S | 1 |
| Araj, GF; Chahine, C; Chedid, M; Moukhachen, O; Sharara, AI | 1 |
| Coyle, W; Dunteman, T; Nemec, R; Sullivan, B | 1 |
| Bengtsson, C; Blennow, M; Casswall, TH; Granström, M; Sörberg, M; Tindberg, Y | 1 |
| Hauser, G; JajacKnez, A; Salkic, N; Stimac, D; Vukelic, K | 1 |
| Abe, A; Hino, H; Hiramoto, M; Kokuba, H; Miyazawa, K; Moriya, S; Takano, N; Takeda, A; Tsukahara, K | 1 |
1 review(s) available for lansoprazole and zithromax
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
11 trial(s) available for lansoprazole and zithromax
| Article | Year |
|---|---|
Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Proton Pump Inhibitors | 1996 |
Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Biopsy; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Duodenal Ulcer; Endoscopy, Digestive System; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Stomach Ulcer; Treatment Outcome | 1997 |
A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Azithromycin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Tinidazole; Treatment Outcome | 1998 |
Evaluation of a new ultrashort triple therapy for Helicobacter pylori disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Azithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Polypharmacy; Prospective Studies; Time Factors; Tinidazole | 1998 |
Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Benzimidazoles; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Pilot Projects; Prospective Studies; Proton Pump Inhibitors; Stomach Ulcer; Sulfoxides; Tinidazole | 1999 |
Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and azithromycin: failure of a "promising" association.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Treatment Failure; Treatment Outcome | 1999 |
Evaluation of lansoprazole (an H+/K+-ATPase inhibitor) and azithromycin (an antibiotic) for control of gastric ulceration in swine during periods of feed deprivation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animal Feed; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Enzyme Inhibitors; Food Deprivation; Helicobacter Infections; Lansoprazole; Omeprazole; Stomach Ulcer; Swine; Swine Diseases | 1999 |
Ultrashort regimen of lansoprazole-amoxicillin-azithromycin for eradicating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lebanon; Omeprazole; Penicillins; Research Design; Safety; Treatment Outcome | 2001 |
Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Prospective Studies; Stomach Diseases | 2002 |
Helicobacter pylori eradication in children and adolescents by a once daily 6-day treatment with or without a proton pump inhibitor in a double-blind randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Azithromycin; Breath Tests; Child; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Tinidazole; Treatment Outcome | 2004 |
Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bifidobacterium; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lacticaseibacillus rhamnosus; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Pantoprazole; Placebos; Probiotics; Prospective Studies; Proton Pump Inhibitors; Surveys and Questionnaires; Treatment Outcome | 2015 |
11 other study(ies) available for lansoprazole and zithromax
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Synergism; Erythromycin; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Organometallic Compounds; Peptic Ulcer; Proton Pump Inhibitors; Roxithromycin | 1998 |
Bactericidal activity of lansoprazole and three macrolides against Helicobacter pylori strains tested by the time-kill kinetic method.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Azithromycin; Biopsy; Clarithromycin; Drug Synergism; Helicobacter pylori; Humans; Kinetics; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Roxithromycin; Time Factors | 1998 |
Combined activity of azithromycin and lansoprazole against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Azithromycin; Drug Synergism; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Proton Pump Inhibitors | 1999 |
Macrolide antibiotics enhance the antitumor effect of lansoprazole resulting in lysosomal membrane permeabilization‑associated cell death.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy-Related Protein 5; Azithromycin; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Gene Knockout Techniques; Humans; Intracellular Membranes; Lansoprazole; Lysosomes; Microscopy, Electron, Transmission; Neoplasms; Permeability | 2020 |